This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Jeffery A. Smisek net worth and biography

Jeffery Smisek Biography and Net Worth

Director of Finch Therapeutics Group

Jeffery Smisek is President of Flight Partners Capital, an investment firm he founded. Previously, Jeffery served as President and Chief Executive Officer of United Airlines Holdings (then United Continental Holdings), also serving as chairman of its board of directors. Prior to this, Jeffery held various roles at Continental Airlines, last serving as President and Chief Executive Officer until the company’s merger with United Airlines. Earlier in his career, Jeffery was a partner at Vinson & Elkins. Jeffery Smisek currently serves on the boards of directors of various private companies and as a member of the board of trustees of Rice University.

Jeffery has an AB from Princeton University and a JD from Harvard Law School.

What is Jeffery A. Smisek's net worth?: The estimated net worth of Jeffery A. Smisek is at least $76,050.90 as of November 22nd, 2023. Mr. Smisek owns 6,642 shares of Finch Therapeutics Group stock worth more than $76,051 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Smisek may own. Learn More about Jeffery A. Smisek's net worth.
How do I contact Jeffery A. Smisek?: The corporate mailing address for Mr. Smisek and other Finch Therapeutics Group executives is , , . Finch Therapeutics Group can also be reached via phone at 617-229-6499 and via email at [email protected]. Learn More on Jeffery A. Smisek's contact information.
Has Jeffery A. Smisek been buying or selling shares of Finch Therapeutics Group?: Jeffery A. Smisek has not been actively trading shares of Finch Therapeutics Group during the last quarter. Most recently, Jeffery A. Smisek sold 6,642 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $2.57, for a transaction totalling $17,069.94. Learn More on Jeffery A. Smisek's trading history.
Who are Finch Therapeutics Group's active insiders?: Finch Therapeutics Group's insider roster includes Nicholas Haft (Director), and Jeffery Smisek (Director). Learn More on Finch Therapeutics Group's active insiders.
Are insiders buying or selling shares of Finch Therapeutics Group?: During the last twelve months, insiders at the sold shares 2 times. They sold a total of 8,112 shares worth more than $22,420.74. The most recent insider tranaction occured on March, 28th when Director Jeffery A. Smisek sold 6,642 shares worth more than $17,069.94. Insiders at Finch Therapeutics Group own 44.9% of the company. Learn More about insider trades at Finch Therapeutics Group.
Information on this page was last updated on 3/28/2024.

Jeffery A. Smisek Insider Trading History at Finch Therapeutics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/28/2024	Sell	6,642	$2.57	$17,069.94
11/22/2023	Sell	1,470	$3.64	$5,350.80	6,642
3/23/2021	Buy	2,941	$510.00	$1,499,910.00

Jeffery A. Smisek Buying and Selling Activity at Finch Therapeutics Group

Finch Therapeutics Group Company Overview

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Today's Range

Now: $11.45

$11.23

$11.45

50 Day Range

MA: $11.65

$11.00

$12.15

2 Week Range

Now: $11.45

$0.80

$14.26

Volume

1,999 shs

Average Volume

27,051 shs

Market Capitalization

$18.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.